@article{7c2652c3097d49f49d1c41f0b18f2a53,
title = "Diagnostic and therapeutic care pathway for fibromyalgia",
abstract = "Early diagnosis and timely and appropriate treatments positively influence the history of fibromyalgia syndrome (FM), with favourable repercussions at clinical, psychological, social and economic levels. Notwithstanding, there are still significant problems with timeliness of diagnosis, access to pharmacological therapies – particularly to innovative ones – and appropriate and effective taking in charge of patients. All the aforementioned factors have a great impact on FM patients{\textquoteright} quality of life. Indeed, even though the World Health Organisation recognised FM as a chronic condition in the International Classification of Diseases 10th edition (ICD-10), many countries still fail to recognise the syndrome, and this negatively influences the capability to appropriately protect and care for patients. This is the case in several European Countries. In Italy, a few Regions have started to put in place precise indications for people suffering from FM, aiming at the implementation of diagnostic-therapeutic pathways. The Diagnostic-Therapeutic Care Pathway (DTCP) provides an important tool to meet the needs of patients suffering from chronic diseases. They present the organisation of an integrated assistance network. This includes a seamless path for disease prevention, diagnosis and treatment, by means of cooperation among physicians and other healthcare professionals.",
keywords = "Chronic disease, Diagnostic-therapeutic care pathway, Fibromyalgia, Health policies, Treatment",
author = "P. Sarzi-Puttini and V. Giorgi and F. Atzeni and R. Gorla and E. Kosek and Choy, {E. H.} and L. Bazzichi and W. H{\"a}user and Ablin, {J. N.} and V. Aloush and D. Buskila and H. Amital and {Da Silva}, {J. A.P.} and S. Perrot and B. Morlion and E. Polati and V. Schweiger and S. Coaccioli and G. Varrassi and {Di Franco}, M. and R. Torta and Forseth, {K. M.{\O}ien} and K. Mannerkorpi and F. Salaffi and {Di Carlo}, M. and G. Cassisi and A. Batticciotto",
note = "Funding Information: E. Kosek reports personal fees for consulting/lecturing from Eli Lilly, Sandoz, UCB Pharma, outside the submitted work. E. Choy has received research grants from Bio-Cancer, Biogen, Novartis, Pfizer, Roche, Sanofi and UCB, consultancy from AbbVie, Am-gen, Biogen, Biocon, Chugai Pharma, Eli Lilly, Gilead, Janssen, Merck Sero-no, Novartis, Pfizer, Regeneron, Roche, R Pharm and Sanofi, speakers fee from AbbVie, Amgen, BMS, Chugai Pharma, Eli Lilly, Galapagos, Gilead, Janssen, Novartis, Pfizer, Regeneron, Roche, Sa-nofi and UCB. W. H{\"a}user has received royalties for a CD with medical hypnosis for fibromyalgia. J.A.P. da Silva is the owner of MyFibromyalgia.org, a virtual clinical centre for the care of patients with fibromyalgia. S. Perrot has received consultancies for Pfizer, Pierre Fabre, Jazz, Lilly and Grunenthal. B. Morlion has served as a consultant for Reckitt-Benekiser, Grunenthal, Pfizer, GSK, and as a speaker for Grunenthal, Krka, GSK Belgium. The other authors have declared no competing interests. Funding Information: We would like to thank the European Network of Fibromyalgia Associations (ENFA) and the Italian Fibromyalgia Syndrome Association (AISF) for the support and help in this work. Publisher Copyright: {\textcopyright} Copyright CliniCal and ExpErimEntal rhEumatology 2021.",
year = "2021",
month = jan,
day = "1",
language = "English",
volume = "39",
journal = "Clinical and Experimental Rheumatology",
issn = "0392-856X",
publisher = "Clinical and Experimental Rheumatology S.A.S.",
number = "3",
}